A Phase 2 study of tarlatamab plus temozolomide in CNS tumors
Recruiting Phase 1,Phase 2 NCT07243470
Study Description
A study testing the combination of tarlatamab and temozolomide in teenagers and adults with brain and spinal cord tumors
Study Details
- Registry ID:
- NCT07243470
- Conditions:
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 70 participants
- Start Date:
- Age Range:
- 12–999 years
- Healthy Volunteers:
- No
Study Locations (14 sites)
-
IUCT - Claudius Regaud
Toulouse, France -
Hôpital de la Timone
Marseille, France -
Hôpital de la Timone - service adulte
Marseille, France -
Hôpital de la Timone - service pédiatrie
Marseille, France -
CHU de Bordeaux
Bordeaux, France -
Hôpital Saint-André
Bordeaux, France -
Hôpital Neurologique Pierre Wertheimer
Bron, France -
Centre Léon Bérard
Lyon, France -
Institut de Cancérologie de l'Ouest
Angers, France -
Hôpital Universitaire d'Angers
Angers, France -
Centre Hospitalier Universitaire d'Angers
Angers, France -
Institut Gustave Roussy
Villejuif, France -
Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix
Paris, France -
Centre Oscar Lambret
Lille, France
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.